Moderna Erases $52B In Value As Rout Deepens To 50%

“Increasing competition and lack of visibility” about future sales has led to a loss of investor interest across the COVID-19 complex, Oppenheimer analyst Hartaj Singh, who has a market perform rating on Moderna, said in an interview. Moderna soared during the pandemic as it raced to develop a COVID-19 vaccine. Impending Federal Reserve interest-rate hikes and…